As the Australian government considers the future of its National Bowel Cancer Screening Program, Australian and US researchers provide compelling evidence of the cost-effectiveness of expanding the national screening program.
Australia has one of the highest colorectal cancer (CRC) mortality rates in the world. Its current screening program (costing about $29 million a year) provides a one-time immunochemical fecal test (iFOBT) for people aged 50, 55, and 65 years. Program funding expires in mid-2011.
A study funded by the Australian government and the US National Cancer Institute, published in the Feb. 21 Medical Journal of Australia, found that expanding the program to screen all 5 million Australians aged 50 -74 years every two years by iFOBT could end up costing only about $50 million more a year, while saving 300 to 500 lives every year.




